RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+31.86%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.4B
AUM Growth
+$6.4B
(+35%)
Cap. Flow
+$641M
Cap. Flow
% of AUM
10.02%
Top 10 Holdings %
Top 10 Hldgs %
53.23%
Holding
81
New
14
Increased
12
Reduced
20
Closed
17
Top Buys
| 1 |
Arvinas
ARVN
|
$173M |
| 2 |
CRGX
CARGO Therapeutics
CRGX
|
$120M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$117M |
| 4 |
Akero Therapeutics
AKRO
|
$83.9M |
| 5 |
Alkermes
ALKS
|
$83.6M |
Top Sells
| 1 |
Thermo Fisher Scientific
TMO
|
$128M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
$28.5M |
| 3 |
Illumina
ILMN
|
$25.8M |
| 4 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
$24.8M |
| 5 |
scPharmaceuticals
SCPH
|
$23.5M |
Sector Composition
| 1 | Healthcare | 99.98% |
| 2 | Financials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Merus
MRUS
$5.04B
| $65.3M | 1.02% |
2,373,625
+376,861
| +19% | +$10.4M |
|
27
Establishment Labs
ESTA
$1.11B
| $64.6M | 1.01% |
2,494,138
| – | – |
|
28
Tarsus Pharmaceuticals
TARS
$2.44B
| $63.8M | 1% |
3,152,341
+271,640
| +9% | +$5.5M |
|
29
89bio
ETNB
$1.37B
| $62.3M | 0.97% |
+5,578,931
| New | +$62.3M |
|
30
Avidity Biosciences
RNA
$6.12B
| $60.5M | 0.95% |
6,689,789
| – | – |
|
31
Apogee Therapeutics
APGE
$2.27B
| $59.9M | 0.94% |
2,142,591
| – | – |
|
32
Insmed
INSM
$30.3B
| $57.8M | 0.9% |
1,865,108
| – | – |
|
33
Orchestra BioMed
OBIO
$147M
| $51.3M | 0.8% |
5,620,640
| – | – |
|
34
Spyre Therapeutics
SYRE
$1.02B
| $48M | 0.75% |
+2,232,760
| New | +$48M |
|
35
Fulcrum Therapeutics
FULC
$353M
| $36.9M | 0.58% |
5,469,956
-348,848
| -6% | -$2.35M |
|
36
Taysha Gene Therapies
TSHA
$791M
| $29.9M | 0.47% |
16,893,185
| – | – |
|
37
Danaher
DHR
$143B
| $27.4M | 0.43% |
+118,584
| New | +$27.4M |
|
|
38
Thermo Fisher Scientific
TMO
$183B
| $26.5M | 0.41% |
50,000
-240,334
| -83% | -$128M |
|
39
UroGen Pharma
URGN
$896M
| $25.9M | 0.4% |
1,726,808
+869,344
| +101% | +$13M |
|
40
RadNet
RDNT
$5.46B
| $23.1M | 0.36% |
+663,602
| New | +$23.1M |
|
|
SWTX
41
DELISTED
SpringWorks Therapeutics
SWTX
| $22.8M | 0.36% |
+625,000
| New | +$22.8M |
|
42
Stoke Therapeutics
STOK
$1.08B
| $21.7M | 0.34% |
4,131,045
-259,513
| -6% | -$1.37M |
|
43
Tango Therapeutics
TNGX
$745M
| $19.5M | 0.3% |
+1,966,752
| New | +$19.5M |
|
44
GH Research
GHRS
$870M
| $19.3M | 0.3% |
3,327,129
| – | – |
|
45
Roivant Sciences
ROIV
$8.6B
| $16.3M | 0.26% |
1,454,273
-98,444
| -6% | -$1.11M |
|
46
Immatics
IMTX
$662M
| $15.6M | 0.24% |
1,484,911
+639,911
| +76% | +$6.74M |
|
47
ESSA Pharma
EPIX
$11.2M
| $15.2M | 0.24% |
+2,298,662
| New | +$15.2M |
|
48
Guardant Health
GH
$8.11B
| $13.3M | 0.21% |
492,977
-7,910
| -2% | -$214K |
|
49
Viridian Therapeutics
VRDN
$1.59B
| $13.2M | 0.21% |
+605,816
| New | +$13.2M |
|
50
Allurion Technologies
ALUR
$16.5M
| $12.9M | 0.2% |
3,457,707
| – | – |
|